by Infertility drugs help boost fertility and stimulate ovulation in women. These drugs help stimulate the development of follicles in the ovaries and sperm production in men. Some common infertility drugs include clomiphene citrate, letrozole, gonadotropins, and aromatase inhibitors. Factors such as sedentary lifestyles, obesity, stress, and health issues are resulting in a rise in infertility cases globally. This is a major driver for the growth of the infertility drugs market.
The global infertility drugs market is estimated to be valued at US$ 4262.17 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Global Infertility Drugs Market Size is the rise in outsourcing of infertility treatments. With advanced fertility clinics emerging across global locations, patients are traveling to other countries for Assisted Reproductive Technology (ART) procedures which have legal, ethical and affordability issues in their home countries. This medical tourism for infertility treatment is contributing significantly to the growth of the market. Another major trend is the increasing research and development activity focused on improving success rates of infertility treatment. Players are investing heavily in developing more effective drugs and advanced treatment procedures to cater to the growing infertility patient pool globally.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the infertility drugs market is moderate. High capital requirements for R&D and manufacturing facilities pose a barrier. However, the introduction of generic versions of drugs pose a threat to established players.
Bargaining power of buyers: The bargaining power of buyers in the infertility drugs market is high. Buyers have a lot of alternatives available and switching costs are low.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. Suppliers of active pharmaceutical ingredients and other raw materials have some pricing power, however increased regulatory norms limit opportunistic behavior.
Threat of new substitutes: The threat of new substitutes is moderate. Advances in fertility services provide alternatives, however medications continue to have advantages in terms of accessibility and costs for treatment.
Competitive rivalry: The competitive rivalry in the infertility market is high. The market is dominated by a few large players. However, the market also sees frequent entry of generic versions intensifying competition.
Key Takeaways
The global Infertility Drugs market is expected to witness high growth over the forecast period. The global infertility drugs market is estimated to be valued at US$ 4262.17 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2031.
Regional analysis
North America holds the largest share of the infertility drugs market and is expected to grow at a high rate owing to rising prevalence of infertility, increasing financial capabilities, and high awareness regarding new infertility treatments.
Key players
Key players operating in the Infertility Drugs market are Koninklijke Philips N.V., LifeWatch USA, Tunstall, Apple Inc., ADT Security Services, Medical Guardian LLC, MobileHelp, Bay Alarm Company, MariCare Oy, Origin Wireless, The ADT Corporation, Singapore Technologies Electronics Limited, Semtech Corporation. Koninklijke Philips N.V. is one of the leading players in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
